Adam W. Cook

*This is an algorithmically generated author record based on publicly available information.

Research Subjects

Research Interests

Adam W. Cook has a total of 24 co-authors. Here are the top co-authors by number of shared publications:

Alexander Drilon
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, USA
86 shared publications
Allison S. Harney
Albert Einstein College of Medicine, Bronx, NY
86 shared publications
Anurag Singh
Pfizer Boulder Research and Development, Boulder, Colorado. 11
86 shared publications
Christina E. Wong
Pfizer Boulder Research Unit, Boulder, Colorado
86 shared publications
Dale Nepert
Pfizer Boulder Research Unit, Boulder, Colorado
86 shared publications
Dylan P. Hartley
Pfizer Boulder Research and Development, Boulder, Colorado. 11
86 shared publications

Latest Publications

Sort by

Open Access
Website
Google Scholar
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Table S8 from SHP2 Inhibition Sensitizes Diverse Oncogene-Addicted Solid Tumors to Re-treatment with Targeted Therapy
by Alexander Drilon, Manish R. Sharma, Melissa L. Johnson, Timothy A. Yap, Shirish Gadgeel, Dale Nepert, Gang Feng, Micaela B. Reddy, Allison S. Harney, Mohamed Elsayed, et al.
Supplementary Table 8: Comparison of clinical safety data for SHP2 inhibitors
Website
Google Scholar
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open Access
Table S8 from SHP2 Inhibition Sensitizes Diverse Oncogene-Addicted Solid Tumors to Re-treatment with Targeted Therapy
by Alexander Drilon, Manish R. Sharma, Melissa L. Johnson, Timothy A. Yap, Shirish Gadgeel, Dale Nepert, Gang Feng, Micaela B. Reddy, Allison S. Harney, Mohamed Elsayed, et al.
Supplementary Table 8: Comparison of clinical safety data for SHP2 inhibitors
Open Access
Website
Google Scholar
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Table S2 from SHP2 Inhibition Sensitizes Diverse Oncogene-Addicted Solid Tumors to Re-treatment with Targeted Therapy
by Alexander Drilon, Manish R. Sharma, Melissa L. Johnson, Timothy A. Yap, Shirish Gadgeel, Dale Nepert, Gang Feng, Micaela B. Reddy, Allison S. Harney, Mohamed Elsayed, et al.
Supplementary Table 2: Phosphatase Profiling of PF-07284892
Website
Google Scholar
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open Access
Table S2 from SHP2 Inhibition Sensitizes Diverse Oncogene-Addicted Solid Tumors to Re-treatment with Targeted Therapy
by Alexander Drilon, Manish R. Sharma, Melissa L. Johnson, Timothy A. Yap, Shirish Gadgeel, Dale Nepert, Gang Feng, Micaela B. Reddy, Allison S. Harney, Mohamed Elsayed, et al.
Supplementary Table 2: Phosphatase Profiling of PF-07284892
Open Access
Website
Google Scholar
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Figure S3 from SHP2 Inhibition Sensitizes Diverse Oncogene-Addicted Solid Tumors to Re-treatment with Targeted Therapy
by Alexander Drilon, Manish R. Sharma, Melissa L. Johnson, Timothy A. Yap, Shirish Gadgeel, Dale Nepert, Gang Feng, Micaela B. Reddy, Allison S. Harney, Mohamed Elsayed, et al.
Supplementary Figure 3: Preclinical development of PF-07284892
Website
Google Scholar
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open Access
Figure S3 from SHP2 Inhibition Sensitizes Diverse Oncogene-Addicted Solid Tumors to Re-treatment with Targeted Therapy
by Alexander Drilon, Manish R. Sharma, Melissa L. Johnson, Timothy A. Yap, Shirish Gadgeel, Dale Nepert, Gang Feng, Micaela B. Reddy, Allison S. Harney, Mohamed Elsayed, et al.
Supplementary Figure 3: Preclinical development of PF-07284892
Open Access
Website
Google Scholar
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Figure S6 from SHP2 Inhibition Sensitizes Diverse Oncogene-Addicted Solid Tumors to Re-treatment with Targeted Therapy
by Alexander Drilon, Manish R. Sharma, Melissa L. Johnson, Timothy A. Yap, Shirish Gadgeel, Dale Nepert, Gang Feng, Micaela B. Reddy, Allison S. Harney, Mohamed Elsayed, et al.
Supplementary Figure 6: PK profiles for patients
Website
Google Scholar
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open Access
Figure S6 from SHP2 Inhibition Sensitizes Diverse Oncogene-Addicted Solid Tumors to Re-treatment with Targeted Therapy
by Alexander Drilon, Manish R. Sharma, Melissa L. Johnson, Timothy A. Yap, Shirish Gadgeel, Dale Nepert, Gang Feng, Micaela B. Reddy, Allison S. Harney, Mohamed Elsayed, et al.
Supplementary Figure 6: PK profiles for patients
Open Access
Website
Google Scholar
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Table S3 from SHP2 Inhibition Sensitizes Diverse Oncogene-Addicted Solid Tumors to Re-treatment with Targeted Therapy
by Alexander Drilon, Manish R. Sharma, Melissa L. Johnson, Timothy A. Yap, Shirish Gadgeel, Dale Nepert, Gang Feng, Micaela B. Reddy, Allison S. Harney, Mohamed Elsayed, et al.
Supplementary Table 3: IC50 values for PF-07284892 in cell-based assays
Website
Google Scholar
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open Access
Table S3 from SHP2 Inhibition Sensitizes Diverse Oncogene-Addicted Solid Tumors to Re-treatment with Targeted Therapy
by Alexander Drilon, Manish R. Sharma, Melissa L. Johnson, Timothy A. Yap, Shirish Gadgeel, Dale Nepert, Gang Feng, Micaela B. Reddy, Allison S. Harney, Mohamed Elsayed, et al.
Supplementary Table 3: IC50 values for PF-07284892 in cell-based assays
Open Access
Website
Google Scholar
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Figure S5 from SHP2 Inhibition Sensitizes Diverse Oncogene-Addicted Solid Tumors to Re-treatment with Targeted Therapy
by Alexander Drilon, Manish R. Sharma, Melissa L. Johnson, Timothy A. Yap, Shirish Gadgeel, Dale Nepert, Gang Feng, Micaela B. Reddy, Allison S. Harney, Mohamed Elsayed, et al.
Supplementary Figure 5: Study schema
Website
Google Scholar
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open Access
Figure S5 from SHP2 Inhibition Sensitizes Diverse Oncogene-Addicted Solid Tumors to Re-treatment with Targeted Therapy
by Alexander Drilon, Manish R. Sharma, Melissa L. Johnson, Timothy A. Yap, Shirish Gadgeel, Dale Nepert, Gang Feng, Micaela B. Reddy, Allison S. Harney, Mohamed Elsayed, et al.
Supplementary Figure 5: Study schema
Open Access
Website
Google Scholar
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Table S6 from SHP2 Inhibition Sensitizes Diverse Oncogene-Addicted Solid Tumors to Re-treatment with Targeted Therapy
by Alexander Drilon, Manish R. Sharma, Melissa L. Johnson, Timothy A. Yap, Shirish Gadgeel, Dale Nepert, Gang Feng, Micaela B. Reddy, Allison S. Harney, Mohamed Elsayed, et al.
Supplementary Table 6: Disposition of all patients enrolled to Dose Level 1
Website
Google Scholar
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open Access
Table S6 from SHP2 Inhibition Sensitizes Diverse Oncogene-Addicted Solid Tumors to Re-treatment with Targeted Therapy
by Alexander Drilon, Manish R. Sharma, Melissa L. Johnson, Timothy A. Yap, Shirish Gadgeel, Dale Nepert, Gang Feng, Micaela B. Reddy, Allison S. Harney, Mohamed Elsayed, et al.
Supplementary Table 6: Disposition of all patients enrolled to Dose Level 1
Open Access
Website
Google Scholar
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Table S7 from SHP2 Inhibition Sensitizes Diverse Oncogene-Addicted Solid Tumors to Re-treatment with Targeted Therapy
by Alexander Drilon, Manish R. Sharma, Melissa L. Johnson, Timothy A. Yap, Shirish Gadgeel, Dale Nepert, Gang Feng, Micaela B. Reddy, Allison S. Harney, Mohamed Elsayed, et al.
Supplementary Table 7: Adverse events for Dose Level 1 patients
Website
Google Scholar
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open Access
Table S7 from SHP2 Inhibition Sensitizes Diverse Oncogene-Addicted Solid Tumors to Re-treatment with Targeted Therapy
by Alexander Drilon, Manish R. Sharma, Melissa L. Johnson, Timothy A. Yap, Shirish Gadgeel, Dale Nepert, Gang Feng, Micaela B. Reddy, Allison S. Harney, Mohamed Elsayed, et al.
Supplementary Table 7: Adverse events for Dose Level 1 patients
Open Access
Website
Google Scholar
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Figure S1 from SHP2 Inhibition Sensitizes Diverse Oncogene-Addicted Solid Tumors to Re-treatment with Targeted Therapy
by Alexander Drilon, Manish R. Sharma, Melissa L. Johnson, Timothy A. Yap, Shirish Gadgeel, Dale Nepert, Gang Feng, Micaela B. Reddy, Allison S. Harney, Mohamed Elsayed, et al.
Supplementary Figure 1: Comparison of the structures of PF-07284892, RMC445507, TNO155 bound to SHP2
Website
Google Scholar
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open Access
Figure S1 from SHP2 Inhibition Sensitizes Diverse Oncogene-Addicted Solid Tumors to Re-treatment with Targeted Therapy
by Alexander Drilon, Manish R. Sharma, Melissa L. Johnson, Timothy A. Yap, Shirish Gadgeel, Dale Nepert, Gang Feng, Micaela B. Reddy, Allison S. Harney, Mohamed Elsayed, et al.
Supplementary Figure 1: Comparison of the structures of PF-07284892, RMC445507, TNO155 bound to SHP2
Open Access
Website
Google Scholar
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Figure S2 from SHP2 Inhibition Sensitizes Diverse Oncogene-Addicted Solid Tumors to Re-treatment with Targeted Therapy
by Alexander Drilon, Manish R. Sharma, Melissa L. Johnson, Timothy A. Yap, Shirish Gadgeel, Dale Nepert, Gang Feng, Micaela B. Reddy, Allison S. Harney, Mohamed Elsayed, et al.
Supplementary Figure 2: Intermittent dosing of PF-07284892 preserves efficacy and improves tolerability preclinically
Website
Google Scholar
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open Access
Figure S2 from SHP2 Inhibition Sensitizes Diverse Oncogene-Addicted Solid Tumors to Re-treatment with Targeted Therapy
by Alexander Drilon, Manish R. Sharma, Melissa L. Johnson, Timothy A. Yap, Shirish Gadgeel, Dale Nepert, Gang Feng, Micaela B. Reddy, Allison S. Harney, Mohamed Elsayed, et al.
Supplementary Figure 2: Intermittent dosing of PF-07284892 preserves efficacy and improves tolerability preclinically

Show all